ArticleFrontiers in oncology2026
Preoperative serum HE4 combined with CA125 testing for predicting the risk of suboptimal cytoreduction in advanced epithelial ovarian cancer.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the predictive value of preoperative serum markers centered on human epididymis protein 4 (HE4) combined with carbohydrate antigen 125 (CA125) for the risk of suboptimal cytoreduction in advanced epithelial ovarian cancer. Methods: We retrospectively analyzed the clinical data of 102 patients with International Federation of Gynecology and Obstetrics (FIGO) stage IIIA-IV epithelial ovarian cancer who underwent primary cytoreductive surgery at the First People's Hospital of Jiangxia District between January 2021 and December 2025. Patients were divided into an optimal cytoreduction group (n=65) and a suboptimal cytoreduction group (n=37) based on the size of postoperative residual lesions. Preoperative HE4 and CA125 levels were compared between the two groups. Restricted cubic spline (RCS) functions were used to analyze dose-response relationships. Multivariate Logistic regression was applied to screen independent risk factors and construct a combined prediction model. Model performance was evaluated using receiver operating characteristic (ROC) curves, calibration curves, and decision curve analysis (DCA). Results: Preoperative HE4, CA125, and platelet counts were significantly higher in the suboptimal cytoreduction group than in the optimal cytoreduction group (all P<0.001). RCS analysis showed a linear positive correlation between marker levels and the risk of suboptimal cytoreduction. Multivariate regression revealed that each 50 pmol/L increase in HE4 (odds ratio [OR]=1.25), each 100 U/mL increase in CA125 (OR = 1.68), and each 10×10 Conclusion: Combined preoperative detection of serum HE4, CA125, and platelet count shows preliminary predictive potential for the risk of suboptimal cytoreduction in advanced epithelial ovarian cancer. In this single-center retrospective cohort, the three-marker combined model demonstrated promising internal predictive performance; however, its clinical applicability remains preliminary and center-specific, pending validation in independent external cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.